Kiora Pharmaceuticals, Inc. Common Stock

The article discusses the advancements in gene therapy for Stargardt disease, a genetic eye disorder, and highlights the significant investment and interest in developing long-term treatments. It mentions over 20 companies working on 25+ pipeline drugs to improve the treatment landscape.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HC Wainwright & Co. has decided to maintain its Buy rating of Kiora Pharmaceuticals (NASDAQ:KPRX) and raise its price target from $3.50 to $2.00. Shares of Kiora Pharmaceuticals are trading down 0.84% over the last 24 hours, at $0.66 per share. A move to $2.00 would account for a 202.57% increase from the current share price. About Kiora Pharmace...

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results. Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly e...

Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share. The company also announced a $50 billion increase to its share repurchase authorization. Meta shares climbed 16.5% to $460.02 in pre-ma...